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Abstract: Osteoarthritis is the most common form of arthritis. It is a progressive joint dis-
ease associated with aging. It may be found in the knees, hips, or other joints. It is estimated 
that costs associated with osteoarthritis exceed 2% of the gross national product in developed 
countries. Nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) are a mainstay in the treatment of 
inﬂ  ammatory disease and are among the most widely used drugs worldwide. The main limitation 
in using NSAIDs consists in their side-effects, including gastrointestinal ulcerogenic activity 
and bronchospasm. The mechanism of action of these drugs is attributed to the inhibition of 
cyclooxygenase (COX), and, consequently, the conversion of arachidonic acid into prostaglan-
dins. It is hypothesized that the undesirable side-effects of NSAIDs are due to the inhibition 
of COX-1 (constitutive isoform), whereas the beneﬁ  cial effects are related to the inhibition of 
COX-2 (inducible isoform). Arachidonic acid can also be converted to leukotrienes (LTs) by 
the action of 5-lipoxygenase (5-LOX). Licofelone, a LOX/COX competitive inhibitor, decreases 
the production of proinﬂ  ammatory leukotrienes and prostaglandins (which are involved in the 
pathophysiology of osteoarthritis and in gastrointestinal (GI) damage induced by NSAIDs) and 
has the potential to combine good analgesic and anti-inﬂ  ammatory effects with excellent GI 
tolerability. Preliminary data with this drug seem promising, but further well-designed clinical 
trials of this agent in the elderly will be necessary before a ﬁ  nal evaluation is possible.
Keywords: LOX/COX inhibitor, Licofelone, leukotrienes, osteoarthritis, nonsteroidal anti-
inﬂ  ammatory drugs
Introduction to degenerative processes 
in osteoarthritis
Osteoarthritis is the most common form of arthritis and the most common indication 
for total hip and total knee replacement. It is a progressive joint disease associated with 
aging. Many elderly people have some degree of osteoarthritis. It may be found in the 
knees, hips, or other joints. Risk factors for the development and/or progression of 
osteoarthritis identiﬁ  ed in epidemiological studies can be broadly divided into systemic 
factors that increase the susceptibility to the disease and local biomechanical factors 
that inﬂ  uence the development of osteoarthritis at the particular joint. It is estimated 
that costs associated with osteoarthritis exceed 2% of the gross national product in 
developed countries. In this context, the clear need for a better understanding of the 
disease process has rendered undeniable the importance of ﬁ  nding drugs that can 
reduce or stop its progression.
The progression of the structural changes that occur during the course of the 
disease is related to a number of complex pathways and mechanisms, among which 
the excess production of proteolytic enzymes that can degrade the cartilage matrix 
and soft tissues surrounding the joint is believed to be of particular importance 
(Martel-Pelletier et al 2004). The degradation of the osteoarthritis cartilage matrix Clinical Interventions in Aging 2007:2(1) 74
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has been shown to be related to the excess synthesis of a 
large number of proteases and, more particularly, to that of 
the matrix metalloproteinases (MMPs) and thioldependent 
families. Among the MMPs, two collagenases, MMP-1 and 
MMP-13, have been the subject of extensive investigation 
and were found likely to be the primary enzymes involved 
in the breakdown of type II collagen in osteoarthritis 
cartilage (Martel-Pelletier et al 2001). Cathepsin K, a thiol-
dependent enzyme that works preferentially under acidic pH 
conditions, has also been demonstrated to be synthesized 
by osteoarthritis chondrocytes and is likewise believed to 
play an important role in the breakdown of the osteoarthritis 
cartilage collagen network (Konttinen et al 2002) as well as 
the aggrecans, and thus likely involved in degrading the car-
tilage extracellular matrix. The mechanisms involved in the 
degradation of the aggrecans in osteoarthritis cartilage have 
also been extensively explored and studied, which has led 
to the identiﬁ  cation of a number of proteolytic enzymes that 
can speciﬁ  cally degrade aggrecans (Nagase and Kashiwagi 
2003). Comprehensive investigation has indicated that the 
MMPs, including MMP-13, aggrecanase-1 (a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS-4), 
and aggrecanase-2 (ADAMTS-5), are the proteolytic enzymes 
that seem the most likely to be involved in the degradation 
of aggrecans in osteoarthritis cartilage (Lark et al 1997; 
Chambers et al 2001).
Recent studies have revealed new and interesting 
information regarding the role played by eicosanoids in the 
pathophysiology of arthritic diseases, including osteoarthritis 
(Hansen et al 1990; Prete and Gurakar-Osborne 1997; Gay 
et al 2001; Jovanovic et al 2001; Martel-Pelletier et al 2003, 
2004). For instance, leukotriene-B4 (LTB4) has proven to 
be an important regulating factor in the synthesis of IL-1β 
by osteoarthritis synovium (Rainsford et al 1996; Jovanovic 
et al 2001; He et al 2002). Both in vitro and in vivo stud-
ies have demonstrated that the excess production of IL-1β 
in osteoarthritis tissue is a key factor in its destruction and 
in the progression of the disease itself (Pelletier et al 2001; 
Martel-Pelletier et al 2004). The endogenous production of 
LTB4 in osteoarthritis synovium is a crucial element in the 
upregulation of IL-1β synthesis in this tissue (He et al 2002). 
The synthesis of LTB4, and subsequently of IL-1β, can be 
signiﬁ  cantly increased by nonsteroidal anti-inﬂ  ammatory 
drugs (NSAIDs) (Parades et al 2002; Marcouiller et al 2005). 
It has been hypothesized that this could be related to a ‘shunt’ 
of the arachidonic acid cascade from the cyclooxygenase 
(COX) to the lipoxygenase (LOX) pathway (Martel-Pelletier 
et al 2003). These ﬁ  ndings could help explain how some 
NSAIDs accelerate the progression of clinical osteoarthritis 
(Huskinsson et al 1995). A recent study has demonstrated 
that, in in vivo experimental osteoarthritis, licofelone, a 
drug that can inhibit both the COX and 5-LOX pathways, 
was capable of reducing the development of osteoarthritis 
structural changes while simultaneously reducing the syn-
thesis of LTB4 and IL-1β by the osteoarthritis synovium 
(Jovanovic et al 2001). These ﬁ  ndings are in strong support 
of the in situ role played by LTB4 in the structural changes 
that occur in osteoarthritis.
Review of pharmacology, mode 
of action, and pharmacokinetics
of licofelone
Arachidonic acid (C20:4), a ω-6 essential fatty acid, is 
metabolized by several enzymes, in different tissues. After 
the cleavage from membrane phospholipids, arachidonic acid 
generates a lot of compounds with a wide range of clinical 
effects involved in inﬂ  ammation. It is very complicated to 
quantitatively determine the ﬁ  nal effect of arachidonic acid 
metabolism resulting from the sum of different actions of 
its metabolites. In fact, just to calculate COX and LOX 
products’ global effect, we have to consider more than 25 
active substances, each with two to ﬁ  ve different actions, 
having different cellular or extracellular tissue and organ 
targets, depending on their different baseline and under-
stimulus production rate (Figure 1) (Bertolini et al 2002). 
A detailed description of the arachidonic acid metabolism 
and the function of its metabolites is not part of the scope 
of this overview; therefore, the different effect of inhibitory 
drugs on COX-1, COX-2, and/or LOX appears to be clini-
cally relevant (Figure 2). The anti-inﬂ  ammatory mechanism 
of action of NSAIDs is attributed to the inhibition of COX, 
and, consequently, the conversion of arachidonic acid into 
prostaglandins. It is hypothesized that the main undesirable 
side-effects of NSAIDs are due to the inhibition of COX-1 
(constitutive isoform), whereas the beneﬁ  cial effects are 
related to the inhibition of COX-2 (inducible isoform). This is 
why selective COX-2 inhibitors seem to be safer with regard 
to gastric damage (Wolfe et al 2002). Arachidonic acid can 
also be converted to LTs by the action of 5-LOX. LT-C4, 
LT-D4 and LT-E4 are potent bronchoconstrictors, whereas 
LT-B4 is chemotactic for leukocytes and plays an important 
role in the development of gastrointestinal ulcers by contrib-
uting to the inﬂ  ammatory process. Thus, developing dual Clinical Interventions in Aging 2007:2(1) 75
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inhibitor compounds that will simultaneously inhibit COX 
and 5-LOX could enhance their individual anti-inﬂ  ammatory 
effects and reduce the undesirable side-effects associated with 
NSAIDs, especially of the gastrointestinal (GI) tract (Fiorucci 
et al 2001). Moreover, lipoxins are also LOX-derived pros-
tanoids, though their biological actions differ dramatically 
from LTs. In fact, lipoxins inhibit bronchoconstriction and 
carry local anti-inﬂ  ammatory signals. Therefore, inhibitors 
of 5-LOX/COX which do not block the 12-LOX and 15-LOX 
pathways should allow unbridled synthesis of lipoxins to 
resolve inﬂ  ammation and attenuate any remaining LT effect 
(Serhan 2001). Several chemically distinct compounds are 
in different phases of preclinical or clinical development: 
BF-389, RWJ 63556, PGV 20229, BW755C, CI-986, SK&F 
105809, FPL 62064, PD 127443, PD 137968, L-652,343, 
CBS-1108, licofelone (ML3000), but none already marketed 
(Celotti and Laufer 2001). The ﬁ  rst one currently involved in phase 
III clinical trials is licofelone (ML3000) ([2,2-dimethy l-6-
(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-
5-yl]-acetic acid) (Reginster et al 2002).
Preclinical data
Preclinical data show that licofelone has anti-inﬂ  ammatory, 
analgesic, antipyretic, and antiplatelet (Laufer et al 1994, 1995; 
Abraham et al 1997; Rotondo et al 2004; Singh et al 2006) 
activities. Licofelone has been shown in vitro to suppress the 
polymorphonuclear (PMN) leukocyteplatelet transcellular 
metabolism of arachidonic acid, prevent PMN aggregation and 
activation, and reduce PMN and platelet adhesion (Rotondo 
et al 2002), all of which are relevant to the pathogenesis of 
inﬂ  ammation.
General toxicological studies in animals have also demon-
strated that licofelone is devoid of deleterious effects on the 
autonomic nervous system, CNS, and cardiovascular system, 
being safe at doses far above pharmacologically active doses 
(Algate et al 1995). In addition, licofelone has no genotoxic 
potential (Heidemann et al 1995).
Further studies in animals have demonstrated that 
licofelone has a lower ulcerogenic potential than aspirin, 
indometacin, and diclofenac (Wallace et al 1994).
Interestingly, in contrast to COX- 2 inhibitors, licofelone does 
not exacerbate gastric mucosal damage, even in aspirin-treated 
rats, thus creating the possibility of concomitant treatment 
with aspirin and licofelone in osteoarthritic patients with 
cardiovascular risk who require long-term aspirin therapy 
(Fiorucci et al 2003). A clinical study conﬁ  rmed that the 
co-administration of low-dose, enteric-coated aspirin and 
licofelone did not produce a clinically relevant increase 
in the occurrence of gastrointestinal ulcers (Buchner et al 
2003). However, the long-term effect of this association on 
cardiovascular outcomes has yet to be determined.
Licofelone also appears to have speciﬁ  c anti-arthritic 
activity in animals. In a rat experimental model of adjuvant 
arthritis, licofelone given at doses ranging between 20 mg/kg 
and 80 mg/kg for 26 days signiﬁ  cantly reduced erythema 
and oedema, as well as arthritis-associated splenomegaly 
(Gay et al 2001). Histological examination of the joints 
also revealed reduced synovial cell proliferation and bone/
cartilage erosions, suggesting selective activity of the drug 
on synovial ﬁ  broblasts.
Prevention of cartilage degradation by licofelone has also 
been observed in an experimental dog model of osteoarthrosis 
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Figure 1 Actions of eicosanoids: from the enzymes to the main effects through the superfamily of metabolic products (simpliﬁ  ed pathway) Copyright © 2002. Modiﬁ  ed 
with permission from Bertolini A, Ottani A, Sandrini M. 2002. Selective COX-2 inhibitors and dual acting anti-inﬂ  ammatory drugs: critical remarks. Curr Med Chem, 9:1033–43.
Abbreviations: COX, cyclooxygenase; LOX, lipoxygenase. Clinical Interventions in Aging 2007:2(1) 76
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in which the anterior cruciate ligament of the stiﬂ  e joint 
was surgically removed (Jovanovic et al 2001; Moreau et al 
2006). Administration of licofelone 2.5–5 mg/kg/day for 8 
weeks signiﬁ  cantly reduced the size and grade of the cartilage 
lesions. In the low-dose group (2.5 mg/kg/day), the size of 
lesions was lowered by 39% on femoral condyles and by 
45% on tibial plateaus in comparison with placebo-treated 
animals, whereas in the high-dose group (5 mg/kg/day) the 
reductions were 64% and 54%, respectively. Moreover, while 
the synovium from placebo-treated dogs was hypertrophic 
and evidently discolored, in dogs treated with licofelone 
the synovium was thinner and the discoloration was less 
intense. Anti-arthritic activity was accompanied not only 
by a combined reduction in the synovial synthesis of PGE2 
and LTB4, but also by a reduction in two major catabolic 
factors involved in cartilage degradation, namely interleukin 
(IL)-1β and collagenase 1. Only intra-articular injections of 
corticosteroid (Pelletier et al 1995) and NSAIDs such as 
tenidap (Sipe et al 1992) have produced similar results, with 
reduced synthesis of IL-1β and IL-6; intra-articular injections 
of the NSAIDs naproxen (Sipe et al 1992), carprofen (Pelletuer 
et al 2000), and tiaprofenic acid (Pelletier and Martel-Pelletier 
1991) did not produce these effects. Furthermore, under the 
same experimental conditions, aspirin may actually accelerate 
cartilage destruction (Palmoski and Brandt 1983). Since LTB4 
plays an important role in the regulation of the synthesis of 
IL-1β, IL-6, and IL-8 in the synovial membrane (Paredes 
et al 2002), the anti-arthritic activity of licofelone may be 
mediated primarily through inhibition of LTB4 synthesis. 
Indeed, selective inhibition of 5-LOX and LTB4 synthesis 
is associated with a reduced production of these cytokines 
in vitro (Rainsford et al 1996). 
All therapeutic potentialities of licofelone, studied by 
international literature, are resumed in Table 1.
Efﬁ  cacy studies and safety
of licofelone in humans
First studies in humans indicate a very good gastric safety, a 
positive effect on bone cell remodelling and on osteoarthritis, 
as well. In an endoscopic study, 121 subjects with normal 
Table 1 Therapeutic potentialities of licofelone
Effects of licofelone from preclinical data
 •  Anti-inﬂ  ammatory
 •  Analgesic
 •  Antipyretic
 •  Antiplatelet
Effects in vitro
  •  Suppression of the PMN leukocyteplatelet transcellular
  •  metabolism of arachidonic acid
  •  Prevention of PMN aggregation and activation
  •  Reduction of PMN and platelet adhesion
Effects in animal models
  •  Reduction of erythema and oedema in osteoarthritis
  •  Reduction of synovial cell proliferation
  •  Reduction of bone/cartilage erosion
Abbreviations: PMN, polymorphonuclear.
Figure 2 Effect of COX-1 and COX-2 inhibition on mechanisms involved in CHD pathogenesis Copyright © 2000. Modiﬁ  ed with permission from Whelton 2000.
Abbreviations: COX, cyclooxygenase; LOX, lipoxygenase; PGI, prostaglandin; TxA, thromboxane A. 
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gastric and duodenal mucosa were randomly assigned a 
4-week treatment with licofelone 200 mg twice daily (bid) or 
400 mg bid, placebo or naproxen 500 mg bid. Groups were 
matched with respect to Helicobacter pylori status (19% 
positive). After 4 weeks the mucosa of the stomach and 
duodenum was endoscopically evaluated. Mean ± standard 
deviation gastric score with both 200 mg and 400 mg bid of 
licofelone were similar to placebo and statistically less than 
with naproxen: 0.13 ± 0.57 (200), 0.14 ± 0.45 (400), 0.20 
± 0.66 (placebo), 1.47 ± 1.31 (naproxen), respectively. The 
gastric mucosa was completely normal in 93%, 89%, 90%, 
and 37% of subjects, respectively.
Duodenal scores were worst with naproxen but not sig-
niﬁ  cantly different among groups in the given sample size: 
0.00, 0.11 ± 0.57, 0.00, 0.20 ± 0.81. The results were qualita-
tively similar in H. pylori positive and negative subgroups. 
Ulcer with unequivocal depth occurred signiﬁ  cantly more 
frequently in naproxen-treated subjects (6/30 = 20%; ﬁ  ve 
gastric ulcers, one duodenal ulcer) than in other groups; no 
ulcer were present in either licofelone group or the placebo 
group (Klesser et al 2002). In another clinical study, 148 
patients with knee osteoarthritis were treated for 12 weeks 
with licofelone 200 mg bid or naproxen 500 mg bid. Efﬁ  cacy 
was evaluated using the Western Ontario and McMaster 
Universities (WOMAC) Osteoarthritis Index. Responders 
were deﬁ  ned to show a 30% improvement versus baseline. 
With licofelone, the mean WOMAC index was improved 
by 23.3 mm and with naproxen there was an improvement by 
21.5 mm. For the WOMAC index, 69.4% of licofelone-treated 
patients were responders (68.4% with naproxen). GI adverse 
events were reported by 13.9% (licofelone) and by 26.3% 
(naproxen) of patients (Reginster et al 2002). A 52-week trial 
was performed to determine the long-term tolerability and 
efﬁ  cacy of licofelone compared with naproxen. This trial 
demonstrated that licofelone was at least as effective as 
naproxen in osteoarthritis treatment (Blanco et al 2003). 
Patients with symptomatic osteoarthritis of the knee (as 
deﬁ  ned by American College of Rheumatology guidelines), 
who had discontinued NSAID therapy 3–14 days prior to the 
baseline visit, were randomized to receive licofelone 100 mg 
bid, licofelone 200 mg bid or naproxen 500 mg bid in this 
multicentre, double-blind, phase III trial. Licofelone treat-
ment was associated with a dose-dependent improvement in 
WOMAC pain scores from baseline. The efﬁ  cacy of licofelone 
200 mg was similar to that of naproxen during the study. Mean 
changes in WOMAC pain scores, from a mean baseline value 
of 63.9 mm, were 27.1 mm, 30.2 mm, and 27.7 mm for licofelone 
100 mg, licofelone 200 mg and naproxen, respectively. 
Adverse event rates again conﬁ  rmed the superior tolerability 
of licofelone compared with naproxen, with patients in the 
100 mg and 200 mg licofelone treatment groups experiencing 
fewer events than those in the naproxen group (59.2%, 56.3%, 
and 66.7%, respectively). In particular, lower frequencies of 
peripheral oedema and aggravated hypertension were recorded 
for licofelone compared with naproxen. Long-term licofelone 
therapy did not result in any clinically relevant variations in 
laboratory parameters or vital signs.
Licofelone 200 mg twice daily was also compared with 
celecoxib 200 mg once daily in a 12-week clinical study of 
patients with symptomatic osteoarthritis of the knee (Pavelka 
et al 2003). Licofelone was as effective as celecoxib, but 
showed better tolerability with a lower incidence of adverse 
events.
Conclusion: place in therapy
LOX/COX inhibitors equally block both the COX-1 and 
COX-2, and the 5-LOX metabolic pathways, inhibiting the 
formation of prostaglandins, thromboxanes, and LTs (Regin-
ster et al 2002). The main reason for the search for a new class 
of anti-inﬂ  ammatory agents is the need for safer drugs, because 
traditional and more recent ones have failed to show a high 
safety proﬁ  le, especially in “frail” patients, as the elderly.
The pharmacological proﬁ  le of LOX/COX inhibitors is 
quite similar to that of glucocorticoids drugs, which inhibit 
PLA2 and thereby prevent arachidonic metabolism by both 
COX and 5-LOX, without the severe adverse events on the 
endocrine system and on the metabolism intermediates of 
PLA2, normally associated with the use of these steroid 
drugs (Parente 2001). What is especially interesting is that 
these drugs seem to positively affect the cartilage metabolism 
thus contrasting the degenerative process of osteoarthritis 
(Jovanovich et al 2001), while signiﬁ  cantly reducing pain and 
pain-related disability. At present time, this seems to be one 
of the more interesting paths for the future development of 
potent-and-safe drugs that can reduce damage derived from 
inappropriate and widespread use of conventional NSAIDs. 
From this point of view, the new class of the LOX/COX 
inhibitors present several beneﬁ  cial and promising therapeutic 
effects that could be very important in the elderly (Skelly and 
Hawkey 2003), and mainly:
a)  potentially higher anti-inflammatory and anti-pain 
efﬁ  cacy;
b)  positive action on the bronchial tract (inhibition of bron-
choconstriction);Clinical Interventions in Aging 2007:2(1) 78
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c)  reduced adverse effects on the upper GI tract, even with 
chronic treatment;
d)  reduced interaction with ASA.
Moreover, dual COX/LOX inhibition could reduce the 
incidence or the progression of many cancers, as assessed 
by many preclinical studies (Leval et al 2002). The main 
limitations of these conclusions are related to the fact that 
we have yet a lack of published data about clinical effective-
ness and safety of COX/LOX dual inhibitors (the most part 
of those reported in this review have been found in posters 
presented at international meetings) and that only licofelone 
has reached the phase III study level. First results on licofelone 
use in humans are very encouraging (Reginster et al 2003), 
but larger clinical trials need to deﬁ  ne its efﬁ  cacy and safety 
and the possibilities of widespread use in the elderly. In fact, 
clinical studies need to be done, aimed at conﬁ  rming these 
clinical effects and safety proﬁ  le of LOX/COX inhibitors in 
the elderly. This last point is very important, since elderly 
will be the ﬁ  rst class of NSAIDs consumers in the future. 
Therefore, it is necessary to adequately study these drugs, 
especially in the pathological conditions of the fragile elderly 
patient or the pluripathologic patient (with a polipharmaco-
therapy), avoiding publication bias caused by missing data.
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